Literature DB >> 6284830

Long term bromocriptine therapy in Cushing's disease.

L P Kapcala, I M Jackson.   

Abstract

Recently, bromocriptine has been successfully introduced as medical therapy for the pituitary hypersecreting syndromes of hyperprolactinemia and acromegaly. Subsequently, an inhibitory effect on ACTH secretion was reported using bromocriptine in Cushing's disease. While most studies have focused on the acute response to bromocriptine, few have investigated the response to chronic therapy with this agent. In this report, we describe a patient with Cushing's disease in whom an acute inhibition of ACTH and cortisol was demonstrated following bromocriptine and in whom the long term administration of bromocriptine as the sole therapy produced a transient beneficial response. Further pharmacologic testing suggested this inhibitory effect on the hypothalamic-pituitary-adrenal axis was mediated through dopaminergic stimulation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284830     DOI: 10.1007/BF03350502

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  16 in total

Review 1.  Substances modulating the secretion of ACTH by cultured anterior pituitary cells.

Authors:  W Vale; C River
Journal:  Fed Proc       Date:  1977-07

2.  Lack of effect of antiserotoninergic and/or dopaminergic treatment in patients with pituitary-dependent Cushing's syndrome.

Authors:  B Ambrosi; M Gaggini; F Secchi; G Faglia
Journal:  Horm Metab Res       Date:  1979-04       Impact factor: 2.936

3.  The role of dopaminergic depletion in the pathogenesis of Cushing's disease and the possible consequences for medical therapy.

Authors:  S W Lamberts; H A Timmermans; F H De Jong; J C Birkenhager
Journal:  Clin Endocrinol (Oxf)       Date:  1977-09       Impact factor: 3.478

4.  Bromocriptine in the treatment of the hyperprolactinaemia-hypogonadism syndromes.

Authors:  G M Besser; M O Thorner
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

Review 5.  The Cushing syndromes: changing views of diagnosis and treatment.

Authors:  E M Gold
Journal:  Ann Intern Med       Date:  1979-05       Impact factor: 25.391

6.  ACTH and cortisol response to bromocriptine, and results of long-term therapy, in Cushing's disease.

Authors:  A L Kennedy; B Sheridan; D A Montgomery
Journal:  Acta Endocrinol (Copenh)       Date:  1978-11

7.  Lack of responsiveness to L-dopa in Cushing's disease.

Authors:  D T Krieger
Journal:  J Clin Endocrinol Metab       Date:  1973-02       Impact factor: 5.958

8.  Effects of growth hormone release-inhibiting hormone and bromocryptine (CB 154) in states of abnormal pituitary-adrenal function.

Authors:  G Benker; K Hackenberg; B Hamburger; D Reinwein
Journal:  Clin Endocrinol (Oxf)       Date:  1976-03       Impact factor: 3.478

9.  Lack of effect of bromocriptine on ACTH levels in patients with bilateral adrenalectomy for pituitary-dependent Cushing's syndrome.

Authors:  N O'Mullane; B Walker; J Jefferson; L Hipkin; M Diver; C Davis
Journal:  J Endocrinol Invest       Date:  1978-10       Impact factor: 4.256

10.  Bromocriptine treatment of acromegaly.

Authors:  M O Thorner; A Chait; M Aitken; G Benker; S R Bloom; C H Mortimer; P Sanders; A S Mason; G M Besser
Journal:  Br Med J       Date:  1975-02-08
View more
  3 in total

1.  Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine.

Authors:  A B Atkinson; A L Kennedy; B Sheridan
Journal:  Postgrad Med J       Date:  1985-03       Impact factor: 2.401

2.  Cushing's disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment.

Authors:  G Verde; P Loli; M E Berselli; M Tagliaferri; D Dallabonzana; G Oppizzi; A Liuzzi; P G Chiodini; G Luccarelli; S Lodrini
Journal:  J Endocrinol Invest       Date:  1984-02       Impact factor: 4.256

Review 3.  Role of "old" pharmacological agents in the treatment of Cushing's syndrome.

Authors:  A G Ambrogio; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2016-04-16       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.